2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors（2018）3.CSF-1R Inhibitor Development: Current Clinical Status（2017）4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
12 June 2023, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”hereafter) today announced that the first patient has been dosed in the phase II trial evaluating its CSF-1R inhibitor, Pimicotinib (ABSK021), in patients with cGVHD. The primary underlying mechanism of cGV...
2.Recent advances of colony-stimulating factor-1 receptor (CSF-1R) kinase and its inhibitors(2018) 3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or ...
研究计划入组约90例受试者,主要终点是基于盲态的独立评审委员会(BIRC)评估的25 周客观缓解率(ORR)。 Abbisko Therapeutics Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor – Pimicotinib(ABSK021) 9 April 2024, Abbisko Therapeutics Co., Ltd. (Abbisko Thera...
Pimicotinib is the first highly selective CSF-1R inhibitor discovered by a Chinese company that entered into a global phase III clinical trial. The study is also the first global Phase III study of TGCT to be conducted simultaneously in China and the US. Approximately 100 participants ar...
3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or more Lines of Systemic Treatment 5.Axatilimab for Chronic Graft-Versus-Host Disease After Failure of...
Pimicotinib is the first highly selective CSF-1R inhibitor discovered by a Chinese company that entered into a global phase III clinical trial. The study is also the first global Phase III study of TGCT to be conducted simultaneously in China, US and Europe. Approximately 100 participants are ...
3.CSF-1R Inhibitor Development: Current Clinical Status(2017) 4.Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or more Lines of Systemic Treatment 5.Axatilimab for Chronic Graft-Versus-Host Disease After Failure of...
1#Breast cancer study uncovers how macrophages may contribute to a therapeutic weak spot(来源:Dana-Farber Cancer Institute) 2#Anita K. Mehta et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nature Cancer (2020)....
[6] Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal ...